Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 129.81 USD 5.85% Market Closed
Market Cap: 7.4B USD
Have any thoughts about
Ascendis Pharma A/S?
Write Note

Ascendis Pharma A/S
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ascendis Pharma A/S
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Ascendis Pharma A/S
NASDAQ:ASND
PP&E Net
€104m
CAGR 3-Years
-6%
CAGR 5-Years
20%
CAGR 10-Years
48%
Genmab A/S
CSE:GMAB
PP&E Net
kr1.9B
CAGR 3-Years
27%
CAGR 5-Years
39%
CAGR 10-Years
55%
Zealand Pharma A/S
CSE:ZEAL
PP&E Net
kr128.9m
CAGR 3-Years
-16%
CAGR 5-Years
6%
CAGR 10-Years
21%
B
Bavarian Nordic A/S
CSE:BAVA
PP&E Net
kr2.4B
CAGR 3-Years
24%
CAGR 5-Years
25%
CAGR 10-Years
22%
F
Fluoguide AS
STO:FLUO
PP&E Net
kr824k
CAGR 3-Years
57%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
PP&E Net
kr1.1m
CAGR 3-Years
-54%
CAGR 5-Years
-27%
CAGR 10-Years
4%
No Stocks Found

Ascendis Pharma A/S
Glance View

Market Cap
7.6B USD
Industry
Biotechnology

Ascendis Pharma A/S is a biopharmaceutical company that is dedicated to transforming the lives of patients through innovative therapies, particularly in the areas of endocrine diseases, oncology, and rare diseases. Founded in 2006 and based in Copenhagen, Denmark, Ascendis has developed a unique platform called TransCon technology, which enables the creation of new medicines that enhance the therapeutic potential of existing drugs. This innovative approach is designed to improve dosing regimens and reduce side effects, positioning Ascendis as a game-changer in the pharmaceutical landscape. With a robust pipeline, including its lead product candidate, TransCon Growth Hormone, currently in late-stage development for growth hormone deficiency, the company is strategically positioned to capture significant market potential. For investors, Ascendis Pharma represents an enticing opportunity within the biopharmaceutical sector, particularly as it navigates pivotal clinical trials and potential regulatory approvals. The company boasts a strong financial foundation, having secured substantial funding from partnerships and public offerings to support its clinical programs. With a growing emphasis on long-term value creation derived from its innovative approach to drug development, Ascendis aims to become a key player in addressing unmet medical needs. As it advances its pipeline and explores partnerships with larger pharmaceutical companies, beckoning the prospects of lucrative collaborations, investors have a chance to become involved in the journey of a company poised at the intersection of science and patient care.

ASND Intrinsic Value
118.13 USD
Overvaluation 9%
Intrinsic Value
Price

See Also

What is Ascendis Pharma A/S's PP&E Net?
PP&E Net
104m EUR

Based on the financial report for Jun 30, 2024, Ascendis Pharma A/S's PP&E Net amounts to 104m EUR.

What is Ascendis Pharma A/S's PP&E Net growth rate?
PP&E Net CAGR 10Y
48%

Over the last year, the PP&E Net growth was -17%. The average annual PP&E Net growth rates for Ascendis Pharma A/S have been -6% over the past three years , 20% over the past five years , and 48% over the past ten years .

Back to Top